Bellicum Outlines Path To Restart US Studies Of Cell Therapy | (BioPharma Dive) Feb 23, 2018 - Bellicum Pharmaceuticals Inc. appears nearer to resolving a clinical hold placed on trials of its lead T-cell therapy last month, outlining on Friday its intention to more thoroughly monitor neurotoxicity risks to patients as part of study revisions required by the Food and Drug Administration. | Read More >>

Add Broken DNA Repair To The List Of Inherited Colorectal Cancer Risk Factors | | Read More >>

| | Read More >>

Puma Biotechnology Receives Results of CHMP Formal Decision for Neratinib for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer | (Morningstar) Feb 23, 2018 - Puma Biotechnology, Inc. announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a negative opinion, recommending the refusal of the Marketing Authorisation Application (MAA) for neratinib for the extended adjuvant treatment of early stage HER2-positive breast cancer. | Read More >>

Is Spending for Infused Chemotherapy By Commercial Insurers Lower at Physician Offices? | (The JAMA Network) Feb 22, 2018 - Bottom Line: Delivering infused chemotherapy in a physician office was associated with lower spending by commercial health insurers compared with chemotherapy administered in a hospital outpatient department. | Read More >>

Scientists Grow 'Mini Tumours' Which Enable Cancer Patients To Have Tailor Made Treatment | | Read More >>

Study Tracks Evolutionary Transition To Destructive Cancer | (Arizona State University) Feb 23, 2018 - Evolution describes how all living forms cope with challenges in their environment, as they struggle to persevere against formidable odds. | Read More >>

Exact Targets Large Hospital Systems to Boost Sales of Cancer Test | | Read More >>

Breast Reconstruction After Radiotherapy Less Risky Without Implants | (University of Auckland [New Zealand]) Feb 23, 2018 - New research from the University of Auckland has found women who use their own tissue in breast reconstruction have fewer post-op complications then women who receive implants. | Read More >>

Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 2 Clinical Trial Evaluating Defibrotide for the Prevention of Acute Graft-versus-Host Disease | (Morningstar) Feb 23, 2018 - Jazz Pharmaceuticals plc today announced that the first patient has been enrolled in a Phase 2 clinical trial evaluating the efficacy and safety of defibrotide for the prevention of acute Graft-versus-Host-Disease (aGvHD) in adult and pediatric patients after allogeneic hematopoietic stem cell transplant (HSCT). | Read More >>

| | Read More >>

Kadmon Announces Updated Positive Results from Phase 2 Study of KD025 in cGVHD | (Morningstar) Feb 22, 2018 - Kadmon Holdings, Inc. today announced updated positive results from an ongoing Phase 2 clinical trial (KD025-208) evaluating KD025, its Rho-associated coiled-coil kinase 2 (ROCK2) inhibitor, in patients with chronic graft-versus-host disease (cGVHD). The results are being presented today in an oral presentation at the BMT Tandem Meetings in Salt Lake City. | Read More >>

GenomeDx Announces Inclusion of Decipher Genomic Testing in NCCN Guidelines for Prostate Cancer | | Read More >>

First Opinion: Community Providers Will Help Drive The Future Of Precision Medicine | (STAT) Feb 23, 2018 - Mundane and subtle obstacles like insurance models, legacy processes, and siloed data are defining the on-the-ground reality for precision medicine. All of those are issues that community providers are well-positioned to address. | Read More >>

Addressing the Opioid Epidemic Without Limiting Appropriate Cancer Care | (ASCO in Action) Feb 22, 2018 - ASCO submitted comments to the Senate Finance Committee on addressing the opioid epidemic in the United States. | Read More >>